Healthcare Global Enterprises Ltd

Healthcare Global Enterprises Ltd Share Price Today: Live Updates & Key Insights

Get insights on Healthcare Global Enterprises Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Healthcare Global Enterprises Ltd Share Price Chart

Healthcare Global Enterprises Ltd Fundamentals

Traded Volume: 1,84,915

Market Cap(Cr): 10,208

Avg Traded Price 729.45

1 Year return 54.53%

Upper Circuit 741.9

Lower Circuit 720.1

P/E TTM 289.00

P/B Ratio 3.00

Traded Value(Cr) 1338.69

EPS TTM 2.509

Book value 2.509

Dividend 0.00%

Healthcare Global Enterprises Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Healthcare Global Enterprises Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Healthcare Global Enterprises Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -3.66%

1M -1.34%

3M +6.10%

1Y +54.53%

YTD +53.21%

Healthcare Global Enterprises Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Healthcare Global Enterprises Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 72259.00

Day Before Yesterday 82441.00

1W Avg 1.19L

1M Avg 2.53L

3M Avg 3.24L

Healthcare Global Enterprises Ltd Technical Details

Healthcare Global Enterprises Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 715

Support 2 707

Support 3 694

Pivot Point : 729

Resistance 1 737

Resistance 2 750

Resistance 3 759

Healthcare Global Enterprises Ltd Corporate Actions

Healthcare Global Enterprises Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Healthcare Global Enterprises Ltd’s capital allocation strategies.

All

Dividends

No Dividend has been declared by HCG

Bonus

No Bonus has been declared by HCG

Splits

No Split has been declared by HCG

Others

Rights No Rights has been declared by HCG

Healthcare Global Enterprises Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Healthcare Global Enterprises Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Healthcare Global Enterprises Ltd's relative performance and valuation against major competitors.

Stock Name Krishna Institute of Medical Sciences Ltd ₹670.10 (-0.44%) M. Cap (Cr) 268.13 1 Yr Return (%) +14.74% P/E (TTM) 79.80 PB Ratio 13.39

Stock Name Dr Agarwals Health Care Ltd ₹493.75 (-0.23%) M. Cap (Cr) 156.11 1 Yr Return (%) NaN% P/E (TTM) 136.16 PB Ratio 10.37

Stock Name Rainbow Childrens Medicare Ltd ₹1330.00 (-0.59%) M. Cap (Cr) 135.07 1 Yr Return (%) -15.49% P/E (TTM) 53.23 PB Ratio 10.05

Stock Name Healthcare Global Enterprises Ltd ₹723.95 (-2.57%) M. Cap (Cr) 102.08 1 Yr Return (%) +54.53% P/E (TTM) 288.52 PB Ratio 11.82

Stock Name Jupiter Life Line Hospitals Ltd ₹1441.00 (-2.03%) M. Cap (Cr) 94.48 1 Yr Return (%) -6.56% P/E (TTM) 47.58 PB Ratio 7.51

Stock Name Yatharth Hospital & Trauma Care Services Ltd ₹758.70 (-1.67%) M. Cap (Cr) 73.10 1 Yr Return (%) +24.31% P/E (TTM) 47.94 PB Ratio 7.75

Stock Name Indraprastha Medical Corporation Ltd ₹516.75 (-2.64%) M. Cap (Cr) 47.37 1 Yr Return (%) +24.25% P/E (TTM) 27.11 PB Ratio 9.03

Healthcare Global Enterprises Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Healthcare Global Enterprises Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 145.95 Mar 2024 194.73 Mar 2023 130.40 Mar 2022 124.40 Mar 2021 70.89

PARTICULARS Investing Activities Mar 2025 -347.33 Mar 2024 -249.22 Mar 2023 -137.70 Mar 2022 48.65 Mar 2021 -245.62

PARTICULARS Financing Activities Mar 2025 -41.55 Mar 2024 105.36 Mar 2023 -41.71 Mar 2022 -41.04 Mar 2021 235.92

PARTICULARS Net Cash Flow Mar 2025 -242.93 Mar 2024 50.87 Mar 2023 -49.02 Mar 2022 132.00 Mar 2021 61.19

Healthcare Global Enterprises Ltd Shareholding Pattern

This shows the ownership breakdown of Healthcare Global Enterprises Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 63.78%

Public 14.28%

Other Institutions 3.73%

FII 3.59%

Mutual Funds 14.63%

About Healthcare Global Enterprises Ltd

Healthcare Global Enterprises Limited was originally incorporated as Curie Centre of Oncology Private Limited on March 12, 1998 at Bengaluru, Karnataka, India as a Private Limited Company. The name of the Company was changed to HealthCare Global Enterprises Private Limited on November 14, 2005. Thereafter, it was converted into a Public Limited Company and the name of the Company was changed to Healthcare Global Enterprises Limited on July 5, 2006.Presently, the Company is engaged in setting up and managing hospitals and medical diagnostic services including scientific testing and consultancy services in the pharmaceutical and medical sector. Under the 'HCG' brand, the Company operates the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB. Under the 'Milann' brand, it operates fertility centres. Milann fertility centres provide comprehensive reproductive medicine services, including assisted reproduction, gynaecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. The Milann network also operates on a model similar to our HCG network, wherein the various Milann fertility centres aim to provide medical services following established protocols with a focus on quality medical care across diagnosis and treatment. It provides comprehensive inpatient and outpatient treatments. Its key specialties include cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary and critical care.Healthcare Global Enterprises provides clinical reference laboratory services in India under the Triesta brand with a specialisation in oncology, including molecular diagnostic services and genomic testing. It has Triesta central reference laboratory located in its centre of excellence in Bengaluru. The Triesta central reference laboratory is accredited by NABL in India, as well as by CAP for quality assurance of laboratory tests performed. Additionally, Triesta offers research and development services to pharmaceutical and biotechnology companies in the areas of clinical trial management and biomarker discovery and validation.The company acquired 50.10% equity interest in BACC Healthcare in 2013 which operates fertility centres under the Milann brand, through itself and its wholly-owned subsidiary, DKR Healthcare. HCG EKO Oncology LLP (HCG EKO LLP) HCG EKO LLP was incorporated on May 15, 2015, under the LLP Act as a limited liability partnership firm. HCG EKO LLP is authorised to primarily engage in the business of setting up hospitals at Kolkata with high end linear accelerators, oncology pharmacy and matters incidental and ancillary thereto.HCG (Mauritius) Pvt. Ltd. (HCG Mauritius) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Mauritius is authorised to hold companies which are primarily engaged in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology. HealthCare Global (Africa) Pvt. Ltd (HCG Africa) was incorporated as a Wholly Owned Subsidiary of the company on May 22, 2015, under the Companies Act, 2001 of Mauritius, as a private limited company. HCG Africa is authorised to engage in the business of treating persons with cancer, carrying on research in the field of oncology and providing various services in the field of oncology and hold companies which are engaged in the same business.Healthcare Global Enterprises entered into a share purchase agreement dated November 23, 2015 with HCG TVH, its erstwhile subsidiary, and Anderson Diagnostics Private Limited. Pursuant to the terms of this agreement, Healthcare Global Enterprises has transferred its entire shareholding in HCG TVH aggregating 51% of the total paid up equity share capital of HCG TVH to Anderson Diagnostics Private Limited for an aggregate consideration of Rs.510,000. Accordingly, HCG TVH has ceased to be the subsidiary of the Company during the Financial Year.During the financial year ended 31 March 2016, Healthcare Global Enterprises transferred its entire shareholding in HealthCare Global (Uganda) Private Limited (HCG Uganda), HealthCare Global (Kenya) Private Limited (HCG Kenya) and HealthCare Global (Tanzania) Private Limited (HCG Tanzania) to HealthCare Global (Africa) Pvt. Ltd. Accordingly, HCG Uganda, HCG Kenya and HCG Tanzania have become level two subsidiaries of the company.During the year under review, Healthcare Global Enterprises introduced two major latest technologies at some of its centres viz. Robotic Surgery and Tomotherapy Treatment System. Robotic Surgery is an advanced form of minimally invasive or laparoscopic (small incision) surgery, where surgeons use a computer-controlled robot to assist them in certain surgical procedures. This facility was installed at Bangalore and Ahmedabad centres. The TomoTherapy treatment system uses a patented multi-leaf collimator (MLC) that divides the radiation beam into beamlets, all aimed at the tumor. More beam directions give physicians more control in how they plan treatments-and more assurance that dose will be confined to the tumor, reducing the risk of short- and long-term side effects. This facility was installed at Kalinga Rao Road centre, Bangalore.During the financial year ended 31 March 2016, the company completed its Initial Public Offering (IPO) of 29,800,000 equity shares of Rs. 10 each, comprising of Fresh Issue of 11,600,000 equity shares and Offer For Sale of 18,200,000 equity shares at a premium of Rs. 208 per equity share. The total issue size was Rs. 6496.4 million. The IPO was open for subscription during the period from 16 to 18 March 2016. The shares got listed the National Stock Exchange of India Limited and BSE Limited on 30 March 2016. In April 2016, HCG launched its first cancer centre in Visakhapatnam, under its subsidiary company, HCG Pinnacle Oncology Private Limited. HCG Pinnacle Cancer Centre has a capacity of upto 88 beds and provides high quality and comprehensive cancer care services. In May 2016, the company launched its new advanced comprehensive cancer centre in Baroda, under its subsidiary, HCG Oncology LLP. The Centre has a bed capacity of 65 beds and is one of the most advanced in terms of technology in the HCG network. HCG Pinnacle Oncology Private Limited, the wholly owned subsidiary of the Company was merged with the Company effective April 01, 2016. The Company launched the first dedicated comprehensive cancer hospital in Mumbai, in May 2017. In June 2017, HCG launched a comprehensive cancer centre in Nagpur, Maharashtra. The Cancer Care Centre in Kenya, Nairobi was acquired in July, 2017. The Company in April, 2018 acquired 12% equity shares of International Stemcell Services Limited from its existing shareholders. HCG Manavata Cancer Centre, Nashik commenced its operations in May, 2018. The Company sold its entire shareholding in HCG Regency Oncology Healthcare Private Limited to Regency Hospital Limited (RHL) and HCG Regency ceased to be a subsidiary of the Company effective from March 29, 2018.The Company commenced operations of the cancer center in Jaipur in 2018-19. The hospital in Bhavnagar commenced operations as comprehensive cancer center with launch of radiation services in the year 2019. The Nashik center commenced operations of phase 2 with a new building adjoining the original hospital, with advanced Tomotherapy Radiation technology, Bone Marrow transplant facilities and 92 beds. Also, the Company acquired 49.99% stake from its minority partner in Apex HCG Oncology Hospitals LLP, which operates the 1st private cancer center in Mumbai. The Company further commenced operations of 2 day care chemotherapy centers in Bengaluru. It commenced operations at 2 centers in Kolkata and South Mumbai.Milann new center in Ahmedabad, launched in 2018, commenced operations in 2019 and Whitefield center was launched in 2019 in Bengaluru region. The hospital in Kolkata commenced launch of operations as comprehensive cancer center including Bone-Marrow Transplant (BMT) facilities in 2020. South Mumbai center was fully operationalised in FY 2020.In FY 2022, the Company acquired an additional 60.9% in Suchirayu Healthcare Solutions, Hubli, Karnataka, from its existing share of 17.7%, to become a majority stake owner. It also acquired the oncology hospital labs and clinical trial business of Strand Life Sciences through a Business Transfer Agreement (BTA).The Company introduced technologies like Next Generation Sequencer in 2023. It became a first center to introduce varian ethos therapy, an AI driven holistic solution of radiation therapy in India. In 2025, it acquired the SRJ CBCC Cancer Hospital in Indore.

Chairman (Non-Executive)

BASAVALINGA AJAIKUMAR SADASHIVAIAH

Registered office HCG Tower No 8 Kalinga Rao Rd, Sampangi Rama Nagar, Bangalore, Karnataka, 560027

FAX :91-80-4660-7700

Background

Incorporation Year 1998

Face Value ₹10.00

Market Lot 1

Healthcare Global Enterprises Ltd Latest News

VIEW MORE NEWS

FAQs on Healthcare Global Enterprises Ltd